, Tracking Stock Market Picks
Enter Symbol:
Keryx Biopharmaceuticals, Inc. (KERX) [hlAlert]

up 117.54 %

Keryx Biopharmaceuticals, Inc. (KERX) rated Buy with price target $25 by Maxim Group

Posted on: Monday,  Jan 27, 2014  8:25 AM ET by Maxim Group

Maxim Group rated Buy Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on 01/27/2014. Previously Maxim Group rated Buy Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on
12/13/2012., when the stock price was $2.85. Since then, Keryx Biopharmaceuticals, Inc. has gained 117.54% as of 01/12/2016's recent price of $6.20.
If you would have followed the previous Maxim Group's recommendation on KERX, you would have gained 117.54% of your investment in 1125 days.

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/28/2014 1:25 PM Buy
15.90 32.00
as of 10/17/2014
1 Week up  2.60 %
1 Month up  12.27 %
3 Months up  12.84 %
1 YTD up  18.68 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/27/2014 8:25 AM Buy
15.10 25.00
8/1/2013 11:25 AM Buy
8.95 12.00
1/28/2013 10:25 AM Buy
4.76 9.00
12/13/2012 9:25 AM Buy
2.85 4.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy